Stocks Health care OLMA
NASDAQ · Health careOlema Pharmaceuticals, Inc. (OLMA)
It posted a net loss of $204.6M. At June 30, 2026 it held $48.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Olema Pharmaceuticals, Inc.
- Net worth
- Olema Pharmaceuticals, Inc. has a market value (market cap) of $636.1M at the latest share price, and shareholders' equity of $430.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $146.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Olema Pharmaceuticals, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Olema Pharmaceuticals, Inc. does
Olema Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker OLMA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$162.5M | -$1.87 | n/a |
| 2024 | n/a | -$129.5M | -$2.20 | -$104.5M |
| 2023 | n/a | -$96.7M | -$2.14 | n/a |
| 2022 | n/a | -$104.8M | -$2.62 | -$82.4M |
| 2021 | n/a | -$71.1M | -$1.80 | -$52.3M |
| 2021 | n/a | -$22.1M | -$3.42 | -$19.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Olema Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 16, 2026Activist stake changed SCHEDULE 13D/A
- October 15, 2026
- August 13, 2026
- August 10, 2026
- August 10, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 23, 2026
- May 26, 2026
- May 21, 2026
Insider trades
What the people running Olema Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 24, 2026 | Harmon CyrusDirector | Sold | 12,500 | $146.4K |
| July 23, 2026 | Harmon CyrusDirector | Sold | 12,500 | $144.7K |
| March 4, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Exercised options | 25,000 | $109.3K |
| March 4, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sold | 24,767 | $600.6K |
| March 4, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sold | 233 | $5.8K |
| March 3, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Exercised options | 15,000 | $65.6K |
| March 3, 2026 | Mitchell ShawnteCHIEF LEGAL OFFICER | Sold | 15,000 | $345.2K |
| February 2, 2026 | Austin Sasha LuVP of Finance and Controller | Received as pay | 11,700 | - |
Who owns OLMA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 13.8% | August 6, 2026 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 9.99% | February 14, 2025 |
| Bvf Partners L P13D, may seek influence with 10 related filers | 9.8% | October 16, 2026 |
| Janus Henderson Group PLC13G, passive | 8.2% | May 15, 2026 |
| Bain Capital Life Sciences Opportunities IV, L.P.13G, passive | 8.15% | May 15, 2026 |
| Graham Walmsley13D, may seek influence with 5 related filers | 5.8% | June 6, 2024 |
| Raymond Debbane13G, passive with 7 related filers | 5.1% | March 20, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 185 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 12,143,062 | +1,756,217 |
| Paradigm Biocapital Advisors LP | 8,670,576 | +650,000 |
| Jupiter Topco LLC | 7,094,413 | new |
| Bain Capital Life Sciences Investors, LLC | 7,085,249 | -387,989 |
| BlackRock, Inc. | 6,714,691 | +1,062,556 |
| Bvf Inc | 5,295,893 | 0 |
| Siren, L.L.C. | 4,856,949 | +100,000 |
| State Street Corp | 4,316,058 | +378,227 |
| Vanguard Capital Management LLC | 3,341,217 | +257,700 |
| Logos Global Management LP | 3,208,875 | 0 |
| Franklin Resources Inc | 2,349,586 | +1,130,629 |
| Cormorant Asset Management, LP | 2,150,000 | -1,750,000 |
| Morgan Stanley | 1,832,269 | +616,579 |
| Geode Capital Management, LLC | 1,819,029 | +274,612 |
| Vanguard Portfolio Management LLC | 1,663,218 | +1,070,187 |
| Goldman Sachs Group Inc | 1,567,979 | +522,390 |
| Deep Track Capital, LP | 1,500,000 | new |
| Dimensional Fund Advisors LP | 1,416,533 | +334,099 |
| Lightspeed Management Company, L.L.C. | 1,355,299 | 0 |
| Kingdon Capital Management, L.L.C. | 1,200,000 | +345,000 |
Insiders
7 insiders reported holding 1,788,663 shares in total, about $13M at the last price.
| Holder | Shares |
|---|---|
| Harmon CyrusDirector | 702,770 |
| Myles David C.CH. DISCOV. & NON-CLIN DEV OFF | 687,607144,846 held indirectly |
| Bohen SeanPresident and CEO, Director | 237,650 |
| Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | 139,727 |
| Austin Sasha LuVP of Finance and Controller | 16,188 |
| Zojwalla NaseemChief Medical Officer | 4,488 |
| Mitchell ShawnteCHIEF LEGAL OFFICER | 233 |
Questions about OLMA
What does Olema Pharmaceuticals, Inc. do?
Olema Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as OLMA. Its shares trade on NASDAQ under the ticker OLMA.
What is Olema Pharmaceuticals, Inc.'s net worth?
Olema Pharmaceuticals, Inc. has a market value (market cap) of $636.1M at the latest share price, and shareholders' equity of $430.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Olema Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $204.6M.
When did Olema Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from October 16, 2026.
When is Olema Pharmaceuticals, Inc.'s next earnings report?
Olema Pharmaceuticals, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare OLMA with
Follow OLMA
Get an email when Olema Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Olema Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.